TAVI NEWS WEEKLY — 14 Sep 2026
What changed this week
[Payer] CMS final TAVR NCD (CAG-00430R2) posted 10 Sep: symptomatic severe AS without CED; asymptomatic severe AS under CED only; revised Heart Team / operator / hospital rules. Operator: ≥20 TC valve (≥15 TAVR)/yr or ≥40 (≥30 TAVR)/2 yr. Dual-operator joint participation not required. Initial heart-team eval may be asynchronous; ≥1 in-person TAVR-operator eval required.
Sources:https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?NCAId=321&proposed=Nhttps://www.beckershospitalreview.com/legal-regulatory-issues/cms-finalizes-tavr-coverage-changes-7-notes/[Market / Payer] ACC / STS / SCAI joint statement 11 Sep welcomes access expansion; stresses Heart Team, TVT Registry, outcomes monitoring, continuous QI.
Source:https://www.acc.org/latest-in-cardiology/articles/2026/09/11/18/54/acc-sts-and-scai-issue-joint-statement-on-tavr-national-coverage-determination[Payer / Other] CMS opens separate NCA for TAVR in aortic regurgitation (CAG-00430R3) 10 Sep; comments through 10 Oct 2026; proposed memo due 10 Mar 2027; expected completion 8 Jun 2027. Triggered with JenaValve Trilogy FDA AR approval context.
Source:https://www.cms.gov/medicare-coverage-database/view/ncacal-tracking-sheet.aspx?ncaid=324Abbott / Edwards / MDT product PR overnight (12–14 Sep): nothing material new.
2. Competitor talking points (cath lab)
[Edwards] Asymptomatic lane: Sapien FDA asymptomatic indication + EARLY TAVR; NCD opens Medicare CED pathway — expect ownership talk. Coverage text remains platform-agnostic for FDA PMA–indicated systems.
[Payer] Programs parsing operator-volume math, single vs dual operator, TVT Registry expectations after society statement.
[MDT] SMART 3-yr small-annuli hemodynamics / BVD vs Sapien still the SEV counterpunch; clinical composite similar.
Source:https://news.medtronic.com/SMART-Trial-three-year-data-demonstrate-superior-benefits-with-Evolut-TAVR-TM-system[Other] JenaValve Trilogy = dedicated AR story while CMS writes AR policy — separate from AS NCD.
3. Navitor leverage points (on-label only)
[Abbott] US label remains symptomatic severe AS, high/extreme surgical risk — do not pitch US low/intermediate or asymptomatic. (Claims review)
[Abbott / Payer] Symptomatic AS: CED dropped for any FDA PMA device used on-label when Heart Team / hospital / operator criteria met — not brand-specific. NCD ≠ expanded US label. (Claims review)
[Abbott] Asymptomatic pathway needs CMS-approved CED and FDA asymptomatic indication — Navitor does not have the latter in the US today. (Claims review)
[Abbott] FIRE TAVI (Clin Res Cardiol): Navitor vs Evolut PRO (269 vs 272) adjusted discharge safety / PPI / gradients similar; >mild PVL lower with Navitor (0.8% vs 3.5%); mortality similar. Registry/observational — fair balance. (Claims review)
Source:https://doi.org/10.1007/s00392-026-02910-w[Abbott] HERA-TAVI: similar 1-yr clinical composite vs Evolut FX/FX+ after PSM; higher PPI with IA-SEV; higher major/LT bleeding with SA-SEV. (Claims review — registry)
Source:https://eurointervention.pcronline.com/article/clinical-and-haemodynamic-outcomes-with-contemporary-intra-and-supra-annular-self-expanding-valves-the-multicentre-international-hera-tavi-registry4. Papers / abstracts to read
CMS Decision Memo CAG-00430R2 (primary)
ACC/STS/SCAI joint statement (11 Sep)
CMS AR NCA tracking sheet CAG-00430R3
FIRE TAVI DOI 10.1007/s00392-026-02910-w
HERA-TAVI — EuroIntervention 2026
SMART 3-yr — EuroPCR / Medtronic May 2026
TCT 2026: PROGRESS primary — 31 Oct–3 Nov
5. Ignore list
Stock tips / analyst “Edwards boost” notes as sales ammo; off-label US low-risk or asymptomatic Navitor pitches; inventing AR coverage timing beyond CMS posted dates; patient-level PHI; X as primary evidence.
Watch: local hospital NCD implementation + AR comment window closes 10 Oct.
